nodes	percent_of_prediction	percent_of_DWPC	metapath
Methamphetamine—SLC22A3—Irinotecan—lung cancer	0.222	0.535	CbGbCtD
Methamphetamine—CYP2D6—Gefitinib—lung cancer	0.0617	0.149	CbGbCtD
Methamphetamine—CYP2D6—Vinorelbine—lung cancer	0.0475	0.115	CbGbCtD
Methamphetamine—CYP2D6—Erlotinib—lung cancer	0.0365	0.0879	CbGbCtD
Methamphetamine—CYP2D6—Vinblastine—lung cancer	0.0293	0.0706	CbGbCtD
Methamphetamine—CYP2D6—Doxorubicin—lung cancer	0.018	0.0434	CbGbCtD
Methamphetamine—TAAR1—respiratory system—lung cancer	0.0131	0.139	CbGeAlD
Methamphetamine—TAAR1—lung—lung cancer	0.00697	0.074	CbGeAlD
Methamphetamine—SLC18A1—lymph node—lung cancer	0.00507	0.0538	CbGeAlD
Methamphetamine—SLC22A5—mammary gland—lung cancer	0.00347	0.0368	CbGeAlD
Methamphetamine—SLC6A3—respiratory system—lung cancer	0.00337	0.0358	CbGeAlD
Methamphetamine—SLC6A4—respiratory system—lung cancer	0.00309	0.0328	CbGeAlD
Methamphetamine—MAOB—respiratory system—lung cancer	0.00294	0.0312	CbGeAlD
Methamphetamine—Pseudoephedrine—IL2—lung cancer	0.00273	0.233	CrCbGaD
Methamphetamine—SLC6A2—respiratory system—lung cancer	0.00272	0.0289	CbGeAlD
Methamphetamine—MAOA—respiratory system—lung cancer	0.00251	0.0266	CbGeAlD
Methamphetamine—MAOB—bronchus—lung cancer	0.00242	0.0257	CbGeAlD
Methamphetamine—SLC18A2—lung—lung cancer	0.00237	0.0251	CbGeAlD
Methamphetamine—SLC22A5—respiratory system—lung cancer	0.00231	0.0245	CbGeAlD
Methamphetamine—Dexfenfluramine—CYP2A6—lung cancer	0.00219	0.187	CrCbGaD
Methamphetamine—MAOA—bronchus—lung cancer	0.00206	0.0219	CbGeAlD
Methamphetamine—MAOB—cardiac atrium—lung cancer	0.00204	0.0217	CbGeAlD
Methamphetamine—ADRA2C—bronchus—lung cancer	0.00199	0.0211	CbGeAlD
Methamphetamine—SLC22A5—bronchus—lung cancer	0.0019	0.0202	CbGeAlD
Methamphetamine—MAOA—trachea—lung cancer	0.00185	0.0197	CbGeAlD
Methamphetamine—SLC6A3—lung—lung cancer	0.00179	0.019	CbGeAlD
Methamphetamine—ADRA2C—trachea—lung cancer	0.00178	0.0189	CbGeAlD
Methamphetamine—MAOA—cardiac atrium—lung cancer	0.00174	0.0185	CbGeAlD
Methamphetamine—SLC22A5—trachea—lung cancer	0.00171	0.0181	CbGeAlD
Methamphetamine—SLC22A3—lung—lung cancer	0.00169	0.0179	CbGeAlD
Methamphetamine—ADRA2C—cardiac atrium—lung cancer	0.00167	0.0178	CbGeAlD
Methamphetamine—SLC6A4—lung—lung cancer	0.00164	0.0174	CbGeAlD
Methamphetamine—SLC18A2—lymph node—lung cancer	0.00162	0.0172	CbGeAlD
Methamphetamine—SLC22A5—cardiac atrium—lung cancer	0.0016	0.017	CbGeAlD
Methamphetamine—ADRA2A—bronchus—lung cancer	0.00158	0.0168	CbGeAlD
Methamphetamine—MAOB—lung—lung cancer	0.00156	0.0166	CbGeAlD
Methamphetamine—Dexfenfluramine—CYP2E1—lung cancer	0.00156	0.133	CrCbGaD
Methamphetamine—Dyspepsia—Crizotinib—lung cancer	0.0015	0.0198	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Crizotinib—lung cancer	0.00148	0.0195	CcSEcCtD
Methamphetamine—Constipation—Crizotinib—lung cancer	0.00146	0.0193	CcSEcCtD
Methamphetamine—SLC6A2—lung—lung cancer	0.00145	0.0153	CbGeAlD
Methamphetamine—Agitation—Teniposide—lung cancer	0.00142	0.0188	CcSEcCtD
Methamphetamine—ADRA2A—trachea—lung cancer	0.00142	0.0151	CbGeAlD
Methamphetamine—Dyspepsia—Pemetrexed—lung cancer	0.00138	0.0181	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Pemetrexed—lung cancer	0.00135	0.0178	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Gefitinib—lung cancer	0.00134	0.0177	CcSEcCtD
Methamphetamine—ADRA2A—cardiac atrium—lung cancer	0.00134	0.0142	CbGeAlD
Methamphetamine—Constipation—Pemetrexed—lung cancer	0.00134	0.0176	CcSEcCtD
Methamphetamine—MAOA—lung—lung cancer	0.00133	0.0141	CbGeAlD
Methamphetamine—Constipation—Gefitinib—lung cancer	0.00133	0.0175	CcSEcCtD
Methamphetamine—ADRA2C—lung—lung cancer	0.00128	0.0136	CbGeAlD
Methamphetamine—Urticaria—Pemetrexed—lung cancer	0.00124	0.0164	CcSEcCtD
Methamphetamine—Tachycardia—Teniposide—lung cancer	0.00124	0.0163	CcSEcCtD
Methamphetamine—Urticaria—Gefitinib—lung cancer	0.00123	0.0163	CcSEcCtD
Methamphetamine—SLC22A5—lung—lung cancer	0.00123	0.013	CbGeAlD
Methamphetamine—Diarrhoea—Crizotinib—lung cancer	0.00117	0.0154	CcSEcCtD
Methamphetamine—SLC22A3—lymph node—lung cancer	0.00115	0.0122	CbGeAlD
Methamphetamine—Hypersensitivity—Pemetrexed—lung cancer	0.00115	0.0152	CcSEcCtD
Methamphetamine—Hypersensitivity—Gefitinib—lung cancer	0.00114	0.0151	CcSEcCtD
Methamphetamine—Dizziness—Crizotinib—lung cancer	0.00113	0.0149	CcSEcCtD
Methamphetamine—Diarrhoea—Pemetrexed—lung cancer	0.00107	0.0141	CcSEcCtD
Methamphetamine—MAOB—lymph node—lung cancer	0.00107	0.0113	CbGeAlD
Methamphetamine—Diarrhoea—Gefitinib—lung cancer	0.00106	0.014	CcSEcCtD
Methamphetamine—Dizziness—Pemetrexed—lung cancer	0.00103	0.0136	CcSEcCtD
Methamphetamine—ADRA2A—lung—lung cancer	0.00102	0.0108	CbGeAlD
Methamphetamine—Urticaria—Teniposide—lung cancer	0.00101	0.0133	CcSEcCtD
Methamphetamine—SLC6A2—lymph node—lung cancer	0.000989	0.0105	CbGeAlD
Methamphetamine—Selegiline—CYP2A6—lung cancer	0.000976	0.0834	CrCbGaD
Methamphetamine—Hypersensitivity—Teniposide—lung cancer	0.000932	0.0123	CcSEcCtD
Methamphetamine—MAOA—lymph node—lung cancer	0.000911	0.00967	CbGeAlD
Methamphetamine—ADRA2C—lymph node—lung cancer	0.000876	0.0093	CbGeAlD
Methamphetamine—Palpitations—Vinorelbine—lung cancer	0.000869	0.0115	CcSEcCtD
Methamphetamine—Diarrhoea—Teniposide—lung cancer	0.000866	0.0114	CcSEcCtD
Methamphetamine—Insomnia—Erlotinib—lung cancer	0.000839	0.0111	CcSEcCtD
Methamphetamine—SLC22A5—lymph node—lung cancer	0.000839	0.0089	CbGeAlD
Methamphetamine—Constipation—Vinblastine—lung cancer	0.000826	0.0109	CcSEcCtD
Methamphetamine—Dyspepsia—Topotecan—lung cancer	0.000826	0.0109	CcSEcCtD
Methamphetamine—Dyspepsia—Erlotinib—lung cancer	0.000817	0.0108	CcSEcCtD
Methamphetamine—Amphetamine—CYP2A6—lung cancer	0.000811	0.0693	CrCbGaD
Methamphetamine—Gastrointestinal disorder—Topotecan—lung cancer	0.00081	0.0107	CcSEcCtD
Methamphetamine—Constipation—Topotecan—lung cancer	0.000802	0.0106	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Erlotinib—lung cancer	0.000801	0.0106	CcSEcCtD
Methamphetamine—Constipation—Erlotinib—lung cancer	0.000794	0.0105	CcSEcCtD
Methamphetamine—Headache—Teniposide—lung cancer	0.000793	0.0105	CcSEcCtD
Methamphetamine—Tachycardia—Vinorelbine—lung cancer	0.000783	0.0103	CcSEcCtD
Methamphetamine—Urticaria—Topotecan—lung cancer	0.000745	0.00983	CcSEcCtD
Methamphetamine—Benzyl alcohol—CYP2E1—lung cancer	0.000722	0.0617	CrCbGaD
Methamphetamine—Benzyl alcohol—CYP1A1—lung cancer	0.000713	0.0609	CrCbGaD
Methamphetamine—Hypersensitivity—Vinblastine—lung cancer	0.000711	0.00938	CcSEcCtD
Methamphetamine—ADRA2A—lymph node—lung cancer	0.000699	0.00742	CbGeAlD
Methamphetamine—Selegiline—CYP2E1—lung cancer	0.000693	0.0592	CrCbGaD
Methamphetamine—Gastrointestinal disorder—Vinorelbine—lung cancer	0.000693	0.00913	CcSEcCtD
Methamphetamine—Hypersensitivity—Topotecan—lung cancer	0.000691	0.00911	CcSEcCtD
Methamphetamine—Tremor—Cisplatin—lung cancer	0.00069	0.0091	CcSEcCtD
Methamphetamine—Constipation—Vinorelbine—lung cancer	0.000686	0.00905	CcSEcCtD
Methamphetamine—Diarrhoea—Vinblastine—lung cancer	0.000661	0.00871	CcSEcCtD
Methamphetamine—Diarrhoea—Topotecan—lung cancer	0.000642	0.00846	CcSEcCtD
Methamphetamine—Dizziness—Vinblastine—lung cancer	0.000638	0.00842	CcSEcCtD
Methamphetamine—Urticaria—Vinorelbine—lung cancer	0.000637	0.00841	CcSEcCtD
Methamphetamine—Diarrhoea—Erlotinib—lung cancer	0.000635	0.00837	CcSEcCtD
Methamphetamine—Dizziness—Topotecan—lung cancer	0.00062	0.00818	CcSEcCtD
Methamphetamine—Tremor—Paclitaxel—lung cancer	0.00062	0.00817	CcSEcCtD
Methamphetamine—Dizziness—Erlotinib—lung cancer	0.000614	0.00809	CcSEcCtD
Methamphetamine—Phenelzine—CYP2E1—lung cancer	0.000611	0.0521	CrCbGaD
Methamphetamine—Agitation—Paclitaxel—lung cancer	0.000608	0.00801	CcSEcCtD
Methamphetamine—Headache—Vinblastine—lung cancer	0.000605	0.00798	CcSEcCtD
Methamphetamine—Insomnia—Irinotecan—lung cancer	0.000598	0.00789	CcSEcCtD
Methamphetamine—Hypersensitivity—Vinorelbine—lung cancer	0.000591	0.0078	CcSEcCtD
Methamphetamine—Headache—Topotecan—lung cancer	0.000588	0.00775	CcSEcCtD
Methamphetamine—Tachycardia—Cisplatin—lung cancer	0.000586	0.00773	CcSEcCtD
Methamphetamine—Palpitations—Paclitaxel—lung cancer	0.000584	0.00771	CcSEcCtD
Methamphetamine—Insomnia—Gemcitabine—lung cancer	0.000583	0.00769	CcSEcCtD
Methamphetamine—Dyspepsia—Irinotecan—lung cancer	0.000582	0.00768	CcSEcCtD
Methamphetamine—Headache—Erlotinib—lung cancer	0.000581	0.00767	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Irinotecan—lung cancer	0.000571	0.00753	CcSEcCtD
Methamphetamine—Constipation—Irinotecan—lung cancer	0.000566	0.00746	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Gemcitabine—lung cancer	0.000556	0.00734	CcSEcCtD
Methamphetamine—Constipation—Gemcitabine—lung cancer	0.000551	0.00727	CcSEcCtD
Methamphetamine—Diarrhoea—Vinorelbine—lung cancer	0.000549	0.00724	CcSEcCtD
Methamphetamine—Tachycardia—Etoposide—lung cancer	0.000537	0.00708	CcSEcCtD
Methamphetamine—Erectile dysfunction—Methotrexate—lung cancer	0.000534	0.00704	CcSEcCtD
Methamphetamine—Dizziness—Vinorelbine—lung cancer	0.000531	0.007	CcSEcCtD
Methamphetamine—Tachycardia—Paclitaxel—lung cancer	0.000527	0.00695	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Cisplatin—lung cancer	0.000519	0.00684	CcSEcCtD
Methamphetamine—Headache—Vinorelbine—lung cancer	0.000503	0.00663	CcSEcCtD
Methamphetamine—Palpitations—Docetaxel—lung cancer	0.000495	0.00653	CcSEcCtD
Methamphetamine—Insomnia—Paclitaxel—lung cancer	0.000488	0.00644	CcSEcCtD
Methamphetamine—Hypersensitivity—Irinotecan—lung cancer	0.000488	0.00643	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Etoposide—lung cancer	0.000475	0.00627	CcSEcCtD
Methamphetamine—Dyspepsia—Paclitaxel—lung cancer	0.000475	0.00626	CcSEcCtD
Methamphetamine—Constipation—Etoposide—lung cancer	0.000471	0.00621	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Paclitaxel—lung cancer	0.000466	0.00614	CcSEcCtD
Methamphetamine—Constipation—Paclitaxel—lung cancer	0.000461	0.00609	CcSEcCtD
Methamphetamine—Diarrhoea—Irinotecan—lung cancer	0.000453	0.00597	CcSEcCtD
Methamphetamine—Tachycardia—Docetaxel—lung cancer	0.000446	0.00589	CcSEcCtD
Methamphetamine—Hypersensitivity—Cisplatin—lung cancer	0.000443	0.00584	CcSEcCtD
Methamphetamine—Diarrhoea—Gemcitabine—lung cancer	0.000441	0.00582	CcSEcCtD
Methamphetamine—Dizziness—Irinotecan—lung cancer	0.000438	0.00577	CcSEcCtD
Methamphetamine—Urticaria—Etoposide—lung cancer	0.000437	0.00577	CcSEcCtD
Methamphetamine—Urticaria—Paclitaxel—lung cancer	0.000429	0.00565	CcSEcCtD
Methamphetamine—Headache—Irinotecan—lung cancer	0.000415	0.00547	CcSEcCtD
Methamphetamine—Insomnia—Docetaxel—lung cancer	0.000414	0.00546	CcSEcCtD
Methamphetamine—Diarrhoea—Cisplatin—lung cancer	0.000411	0.00542	CcSEcCtD
Methamphetamine—Hypersensitivity—Etoposide—lung cancer	0.000406	0.00535	CcSEcCtD
Methamphetamine—Headache—Gemcitabine—lung cancer	0.000404	0.00533	CcSEcCtD
Methamphetamine—Dyspepsia—Docetaxel—lung cancer	0.000403	0.00531	CcSEcCtD
Methamphetamine—Hypersensitivity—Paclitaxel—lung cancer	0.000398	0.00524	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Docetaxel—lung cancer	0.000395	0.00521	CcSEcCtD
Methamphetamine—Constipation—Docetaxel—lung cancer	0.000391	0.00516	CcSEcCtD
Methamphetamine—Diarrhoea—Etoposide—lung cancer	0.000377	0.00497	CcSEcCtD
Methamphetamine—Diarrhoea—Paclitaxel—lung cancer	0.000369	0.00487	CcSEcCtD
Methamphetamine—Dizziness—Etoposide—lung cancer	0.000364	0.0048	CcSEcCtD
Methamphetamine—Selegiline—ABCB1—lung cancer	0.000363	0.031	CrCbGaD
Methamphetamine—Dizziness—Paclitaxel—lung cancer	0.000357	0.00471	CcSEcCtD
Methamphetamine—Headache—Etoposide—lung cancer	0.000345	0.00455	CcSEcCtD
Methamphetamine—Nateglinide—ALB—lung cancer	0.00034	0.0291	CrCbGaD
Methamphetamine—Headache—Paclitaxel—lung cancer	0.000338	0.00446	CcSEcCtD
Methamphetamine—Hypersensitivity—Docetaxel—lung cancer	0.000337	0.00444	CcSEcCtD
Methamphetamine—Agitation—Doxorubicin—lung cancer	0.000321	0.00424	CcSEcCtD
Methamphetamine—Diarrhoea—Docetaxel—lung cancer	0.000313	0.00413	CcSEcCtD
Methamphetamine—Palpitations—Doxorubicin—lung cancer	0.000309	0.00408	CcSEcCtD
Methamphetamine—Dizziness—Docetaxel—lung cancer	0.000302	0.00399	CcSEcCtD
Methamphetamine—Insomnia—Methotrexate—lung cancer	0.000298	0.00393	CcSEcCtD
Methamphetamine—Dyspepsia—Methotrexate—lung cancer	0.00029	0.00383	CcSEcCtD
Methamphetamine—Headache—Docetaxel—lung cancer	0.000287	0.00378	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Methotrexate—lung cancer	0.000285	0.00375	CcSEcCtD
Methamphetamine—Tachycardia—Doxorubicin—lung cancer	0.000279	0.00367	CcSEcCtD
Methamphetamine—Urticaria—Methotrexate—lung cancer	0.000262	0.00345	CcSEcCtD
Methamphetamine—Insomnia—Doxorubicin—lung cancer	0.000258	0.00341	CcSEcCtD
Methamphetamine—Dyspepsia—Doxorubicin—lung cancer	0.000251	0.00331	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Doxorubicin—lung cancer	0.000246	0.00325	CcSEcCtD
Methamphetamine—Constipation—Doxorubicin—lung cancer	0.000244	0.00322	CcSEcCtD
Methamphetamine—Hypersensitivity—Methotrexate—lung cancer	0.000243	0.0032	CcSEcCtD
Methamphetamine—Urticaria—Doxorubicin—lung cancer	0.000227	0.00299	CcSEcCtD
Methamphetamine—Diarrhoea—Methotrexate—lung cancer	0.000226	0.00297	CcSEcCtD
Methamphetamine—Dizziness—Methotrexate—lung cancer	0.000218	0.00288	CcSEcCtD
Methamphetamine—Hypersensitivity—Doxorubicin—lung cancer	0.00021	0.00277	CcSEcCtD
Methamphetamine—Headache—Methotrexate—lung cancer	0.000207	0.00272	CcSEcCtD
Methamphetamine—Diarrhoea—Doxorubicin—lung cancer	0.000195	0.00258	CcSEcCtD
Methamphetamine—Dizziness—Doxorubicin—lung cancer	0.000189	0.00249	CcSEcCtD
Methamphetamine—Headache—Doxorubicin—lung cancer	0.000179	0.00236	CcSEcCtD
Methamphetamine—ADRA2C—Metabolism—APOA1—lung cancer	2.57e-05	6.37e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—POMC—lung cancer	2.57e-05	6.36e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—GSTM1—lung cancer	2.56e-05	6.36e-05	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—PTEN—lung cancer	2.54e-05	6.31e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—PIK3CB—lung cancer	2.54e-05	6.3e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—STK11—lung cancer	2.52e-05	6.25e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—PIK3CD—lung cancer	2.51e-05	6.21e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—IL6R—lung cancer	2.5e-05	6.2e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—IL2—lung cancer	2.5e-05	6.2e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—HRAS—lung cancer	2.5e-05	6.19e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—TERT—lung cancer	2.49e-05	6.17e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—ALB—lung cancer	2.47e-05	6.13e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—ENO1—lung cancer	2.46e-05	6.09e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—CXCL8—lung cancer	2.44e-05	6.06e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—FOXO3—lung cancer	2.43e-05	6.03e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—CYP1A1—lung cancer	2.43e-05	6.03e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—ERBB3—lung cancer	2.43e-05	6.02e-05	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—EP300—lung cancer	2.43e-05	6.02e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—FGFR1—lung cancer	2.42e-05	6e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—ERCC2—lung cancer	2.41e-05	5.98e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—KRAS—lung cancer	2.39e-05	5.92e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—MAP2K1—lung cancer	2.38e-05	5.91e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—HIF1A—lung cancer	2.38e-05	5.91e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—PIK3CD—lung cancer	2.37e-05	5.87e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—AKT1—lung cancer	2.36e-05	5.86e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—PIK3CG—lung cancer	2.34e-05	5.81e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—IL2—lung cancer	2.33e-05	5.79e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—TERT—lung cancer	2.33e-05	5.77e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—APOA1—lung cancer	2.3e-05	5.7e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—AVP—lung cancer	2.28e-05	5.65e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—KDR—lung cancer	2.28e-05	5.65e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—PIK3CB—lung cancer	2.27e-05	5.64e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—FGFR1—lung cancer	2.26e-05	5.6e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—POMC—lung cancer	2.23e-05	5.53e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—HIF1A—lung cancer	2.22e-05	5.52e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—AKT1—lung cancer	2.21e-05	5.47e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CYP2E1—lung cancer	2.2e-05	5.47e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—IGF1R—lung cancer	2.19e-05	5.44e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—PIK3CA—lung cancer	2.19e-05	5.44e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—CXCL8—lung cancer	2.19e-05	5.42e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—PIK3CB—lung cancer	2.18e-05	5.41e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—NQO1—lung cancer	2.18e-05	5.41e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—CREBBP—lung cancer	2.17e-05	5.39e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—PTGS2—lung cancer	2.16e-05	5.36e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—HES1—lung cancer	2.16e-05	5.35e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—APOA1—lung cancer	2.15e-05	5.32e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—KDR—lung cancer	2.13e-05	5.28e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—TP53—lung cancer	2.12e-05	5.26e-05	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—PIK3CA—lung cancer	2.12e-05	5.26e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—RAF1—lung cancer	2.11e-05	5.24e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—PIK3CG—lung cancer	2.1e-05	5.2e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—APC—lung cancer	2.1e-05	5.2e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—KIT—lung cancer	2.1e-05	5.2e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—NRAS—lung cancer	2.1e-05	5.2e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—IL2—lung cancer	2.09e-05	5.18e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—APOA1—lung cancer	2.09e-05	5.17e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—EGF—lung cancer	2.07e-05	5.14e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—PIK3CB—lung cancer	2.06e-05	5.12e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—PIK3CD—lung cancer	2.06e-05	5.11e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—ALB—lung cancer	2.03e-05	5.04e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—HRAS—lung cancer	2.03e-05	5.03e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—MAPK3—lung cancer	2.01e-05	4.98e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—POMC—lung cancer	2e-05	4.95e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—CXCL8—lung cancer	1.98e-05	4.92e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—BRAF—lung cancer	1.97e-05	4.89e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—ERBB3—lung cancer	1.97e-05	4.89e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—STK11—lung cancer	1.96e-05	4.87e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—PIK3CG—lung cancer	1.96e-05	4.86e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—APC—lung cancer	1.96e-05	4.86e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—KIT—lung cancer	1.96e-05	4.86e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—NRAS—lung cancer	1.96e-05	4.86e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—IL6R—lung cancer	1.95e-05	4.83e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CREBBP—lung cancer	1.95e-05	4.82e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—EGF—lung cancer	1.94e-05	4.8e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—EGFR—lung cancer	1.91e-05	4.74e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—PIK3CG—lung cancer	1.9e-05	4.72e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—IL2—lung cancer	1.9e-05	4.7e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—TERT—lung cancer	1.89e-05	4.69e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—PTEN—lung cancer	1.89e-05	4.68e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—MAPK3—lung cancer	1.88e-05	4.65e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—POMC—lung cancer	1.87e-05	4.63e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—MAP2K1—lung cancer	1.86e-05	4.6e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—PIK3CD—lung cancer	1.84e-05	4.57e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—BRAF—lung cancer	1.84e-05	4.57e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—FGFR1—lung cancer	1.83e-05	4.55e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—PIK3CA—lung cancer	1.83e-05	4.53e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—IL6R—lung cancer	1.82e-05	4.51e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—GSTP1—lung cancer	1.82e-05	4.51e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CREBBP—lung cancer	1.82e-05	4.51e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—POMC—lung cancer	1.81e-05	4.49e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—HIF1A—lung cancer	1.81e-05	4.48e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—KRAS—lung cancer	1.81e-05	4.48e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—EP300—lung cancer	1.8e-05	4.46e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—PIK3CB—lung cancer	1.8e-05	4.45e-05	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—PIK3CA—lung cancer	1.79e-05	4.45e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—AKT1—lung cancer	1.79e-05	4.44e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—EGFR—lung cancer	1.79e-05	4.43e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—PTGS2—lung cancer	1.78e-05	4.41e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CAT—lung cancer	1.77e-05	4.39e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—CREBBP—lung cancer	1.77e-05	4.38e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—APOA1—lung cancer	1.74e-05	4.32e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—MAP2K1—lung cancer	1.73e-05	4.3e-05	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—AKT1—lung cancer	1.73e-05	4.3e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—KDR—lung cancer	1.73e-05	4.29e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—PIK3CD—lung cancer	1.72e-05	4.27e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—ABCB1—lung cancer	1.72e-05	4.27e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—PIK3CA—lung cancer	1.71e-05	4.23e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—TYMS—lung cancer	1.69e-05	4.19e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—KRAS—lung cancer	1.69e-05	4.18e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—PIK3CD—lung cancer	1.67e-05	4.15e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—GSTM1—lung cancer	1.67e-05	4.14e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—PIK3CA—lung cancer	1.66e-05	4.11e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—MDM2—lung cancer	1.65e-05	4.1e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—ALB—lung cancer	1.65e-05	4.1e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—RAF1—lung cancer	1.65e-05	4.08e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—ERBB2—lung cancer	1.63e-05	4.04e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—MTOR—lung cancer	1.61e-05	3.99e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—PIK3CB—lung cancer	1.61e-05	3.99e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PIK3CG—lung cancer	1.59e-05	3.95e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—KIT—lung cancer	1.59e-05	3.95e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—APC—lung cancer	1.59e-05	3.95e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—NRAS—lung cancer	1.59e-05	3.95e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CYP1A1—lung cancer	1.58e-05	3.93e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—EGF—lung cancer	1.57e-05	3.9e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—ERCC2—lung cancer	1.57e-05	3.89e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—PTEN—lung cancer	1.55e-05	3.85e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—PIK3CA—lung cancer	1.55e-05	3.84e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CXCL8—lung cancer	1.54e-05	3.83e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—MDM2—lung cancer	1.54e-05	3.83e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—RAF1—lung cancer	1.54e-05	3.81e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—HRAS—lung cancer	1.53e-05	3.81e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—MAPK3—lung cancer	1.52e-05	3.78e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—ERBB2—lung cancer	1.52e-05	3.77e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—POMC—lung cancer	1.52e-05	3.76e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—MTOR—lung cancer	1.5e-05	3.72e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—PIK3CB—lung cancer	1.5e-05	3.72e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—BRAF—lung cancer	1.5e-05	3.71e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—AKT1—lung cancer	1.49e-05	3.7e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—EP300—lung cancer	1.48e-05	3.67e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CASP3—lung cancer	1.48e-05	3.67e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—IL6R—lung cancer	1.48e-05	3.67e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—IL2—lung cancer	1.48e-05	3.66e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CREBBP—lung cancer	1.48e-05	3.66e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—IL6—lung cancer	1.47e-05	3.64e-05	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—AKT1—lung cancer	1.47e-05	3.64e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—PIK3CB—lung cancer	1.46e-05	3.62e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—EGFR—lung cancer	1.45e-05	3.6e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—PTGS2—lung cancer	1.45e-05	3.58e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CXCL8—lung cancer	1.44e-05	3.58e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CCND1—lung cancer	1.44e-05	3.57e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—JUN—lung cancer	1.44e-05	3.56e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—HRAS—lung cancer	1.43e-05	3.56e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—MAP2K1—lung cancer	1.41e-05	3.49e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PIK3CD—lung cancer	1.4e-05	3.47e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—MMP9—lung cancer	1.4e-05	3.47e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—AKT1—lung cancer	1.39e-05	3.46e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CDKN1A—lung cancer	1.39e-05	3.45e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—PTEN—lung cancer	1.39e-05	3.44e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—PIK3CA—lung cancer	1.39e-05	3.44e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CASP3—lung cancer	1.38e-05	3.43e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—IL2—lung cancer	1.38e-05	3.42e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—IL6—lung cancer	1.37e-05	3.4e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—KRAS—lung cancer	1.37e-05	3.4e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—APOA1—lung cancer	1.36e-05	3.37e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—AKT1—lung cancer	1.36e-05	3.36e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CCND1—lung cancer	1.34e-05	3.33e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—JUN—lung cancer	1.34e-05	3.33e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—PIK3CA—lung cancer	1.33e-05	3.3e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—EP300—lung cancer	1.32e-05	3.29e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—MMP9—lung cancer	1.31e-05	3.24e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CDKN1A—lung cancer	1.3e-05	3.23e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—PTEN—lung cancer	1.3e-05	3.22e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—SRC—lung cancer	1.29e-05	3.19e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—AKT1—lung cancer	1.27e-05	3.14e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—PTEN—lung cancer	1.26e-05	3.13e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—PIK3CA—lung cancer	1.26e-05	3.12e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—VEGFA—lung cancer	1.25e-05	3.11e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—MDM2—lung cancer	1.25e-05	3.11e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—RAF1—lung cancer	1.25e-05	3.1e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—STAT3—lung cancer	1.24e-05	3.08e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PIK3CG—lung cancer	1.24e-05	3.08e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—NRAS—lung cancer	1.24e-05	3.07e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—EP300—lung cancer	1.24e-05	3.07e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—ERBB2—lung cancer	1.24e-05	3.06e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—MTOR—lung cancer	1.22e-05	3.02e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PIK3CB—lung cancer	1.22e-05	3.02e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—SRC—lung cancer	1.2e-05	2.98e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—EP300—lung cancer	1.2e-05	2.98e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—MAPK3—lung cancer	1.19e-05	2.94e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—POMC—lung cancer	1.18e-05	2.93e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CXCL8—lung cancer	1.17e-05	2.91e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—VEGFA—lung cancer	1.17e-05	2.91e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—HRAS—lung cancer	1.16e-05	2.89e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—STAT3—lung cancer	1.16e-05	2.88e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—NRAS—lung cancer	1.16e-05	2.87e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—MYC—lung cancer	1.15e-05	2.86e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CREBBP—lung cancer	1.15e-05	2.85e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—AKT1—lung cancer	1.13e-05	2.81e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—EGFR—lung cancer	1.13e-05	2.8e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CASP3—lung cancer	1.12e-05	2.78e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—IL2—lung cancer	1.12e-05	2.78e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—IL6—lung cancer	1.11e-05	2.76e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—MAPK3—lung cancer	1.11e-05	2.75e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—PIK3CA—lung cancer	1.09e-05	2.71e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CCND1—lung cancer	1.09e-05	2.71e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PIK3CD—lung cancer	1.09e-05	2.7e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—JUN—lung cancer	1.09e-05	2.7e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—AKT1—lung cancer	1.09e-05	2.7e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—MYC—lung cancer	1.08e-05	2.67e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—ALB—lung cancer	1.08e-05	2.67e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—KRAS—lung cancer	1.07e-05	2.65e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—MMP9—lung cancer	1.06e-05	2.63e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CDKN1A—lung cancer	1.06e-05	2.62e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—EGFR—lung cancer	1.05e-05	2.62e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PTEN—lung cancer	1.05e-05	2.61e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—AKT1—lung cancer	1.03e-05	2.55e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—EP300—lung cancer	1.01e-05	2.49e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—KRAS—lung cancer	9.96e-06	2.47e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—PIK3CA—lung cancer	9.8e-06	2.43e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—SRC—lung cancer	9.78e-06	2.42e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—VEGFA—lung cancer	9.52e-06	2.36e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PIK3CB—lung cancer	9.51e-06	2.36e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—TP53—lung cancer	9.48e-06	2.35e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—STAT3—lung cancer	9.43e-06	2.34e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PTGS2—lung cancer	9.42e-06	2.34e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—NRAS—lung cancer	9.4e-06	2.33e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—PIK3CA—lung cancer	9.15e-06	2.27e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—HRAS—lung cancer	9.07e-06	2.25e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—MAPK3—lung cancer	9.01e-06	2.23e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—AKT1—lung cancer	8.94e-06	2.22e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—PIK3CA—lung cancer	8.89e-06	2.21e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—TP53—lung cancer	8.86e-06	2.2e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—MYC—lung cancer	8.76e-06	2.17e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—IL6—lung cancer	8.68e-06	2.15e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—EGFR—lung cancer	8.57e-06	2.12e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—HRAS—lung cancer	8.47e-06	2.1e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PTEN—lung cancer	8.21e-06	2.04e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—IL6—lung cancer	8.11e-06	2.01e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—KRAS—lung cancer	8.09e-06	2.01e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—AKT1—lung cancer	8.01e-06	1.99e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—EP300—lung cancer	7.83e-06	1.94e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—AKT1—lung cancer	7.48e-06	1.85e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PIK3CA—lung cancer	7.44e-06	1.84e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—AKT1—lung cancer	7.26e-06	1.8e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—TP53—lung cancer	7.19e-06	1.78e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—HRAS—lung cancer	6.88e-06	1.71e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—IL6—lung cancer	6.58e-06	1.63e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—AKT1—lung cancer	6.07e-06	1.51e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PIK3CA—lung cancer	5.79e-06	1.44e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—AKT1—lung cancer	4.73e-06	1.17e-05	CbGpPWpGaD
